MERTK and metabolic dysfunction-associated steatotic liver disease: Our evidence suggests that detection of the MERTK polymorphic status rs4374383, along with rs6726639, should warn in favor of more stringent monitoring to early detect disease progression and cancer development in patients with CHC and CHB and genotype AA/AG or progression to cirrhosis and its complications in patients with NAFLD and genotype GG/AG (9–11).